Onlyglim-MV 2 Tablet SR is a combination oral antidiabetic medication containing Glimepiride 2mg, Metformin 500mg, and Voglibose 0.2mg, designed for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to enhance insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, contributing to better glycemic control without causing significant hypoglycemia. Voglibose, an alpha-glucosidase inhibitor, delays carbohydrate absorption from the gastrointestinal tract, resulting in reduced postprandial hyperglycemia. The sustained-release formulation ensures a gradual and prolonged release of active ingredients, improving patient compliance and minimizing gastrointestinal side effects commonly associated with immediate-release formulations. Onlyglim-MV 2 Tablet SR is indicated for patients inadequately controlled on diet and exercise alone or those requiring combination therapy to achieve optimal glycemic targets. It should be used under medical supervision with regular monitoring of blood glucose levels, renal function, and liver enzymes. Caution is advised in patients with renal impairment, hepatic dysfunction, or a history of lactic acidosis. This combination therapy offers a comprehensive approach to managing hyperglycemia by targeting multiple pathophysiological defects in type 2 diabetes.